Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

June 30, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

Multimeric-001, 500 mcg

Adjuvanted Multimeric-001 was administered twice with an interval of 19-23 days.

BIOLOGICAL

Adjuvanted PBS

Adjuvanted PBS was administered twice with an interval of 19-23 days.

BIOLOGICAL

PBS and TIV 15%

PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 15% dose of commercial seasonal trivalent vaccine (season 2011) was administered.

BIOLOGICAL

PBS and TIV 50%

PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 50% dose of commercial seasonal trivalent vaccine (season 2011) was administered.

Trial Locations (2)

Unknown

Clinical Research Center, Hadassah Medical Center, Jerusalem

Clinical Research Center, Tel-Aviv Sourasky Medical Center, Tel Aviv

Sponsors
All Listed Sponsors
lead

BiondVax Pharmaceuticals ltd.

INDUSTRY